Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole

References

• Guiloff RJ, Goonetilleke A. Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross amyotrophic lateral sclerosis rating scales. Adv Neurol. 1995;68:185–98.
   Google Scholar
• Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle & Nerve. 1989;12:833–41.
   PubMed Web of Science ®Google Scholar
• Christensen PB, Hojer-Pederson E, Jensen NB. Survival of patients with amyotrophic lateral sclerosis in two Danish counties. Neurology. 1990;40:600–4.
   PubMed Web of Science ®Google Scholar
• Eisen A, Schulzer M, Macneil M, Pant B. Duration of amyotrophic lateral sclerosis in age dependent. Muscle & Nerve. 1993;16:27–32.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 1994;13:226–35.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–19.
   Google Scholar
• Preux PM, Couratier P, Boutros-Toni F, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiol. 1996;16:153–60.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS consortium. J Neurol Sci. 1997; 152(Suppl 1):S10–7.
   Google Scholar
• Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. Neurology. 1998;50:66–72.
   PubMed Web of Science ®Google Scholar
• Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059–63.
   PubMed Web of Science ®Google Scholar
• Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg. 2000;100:84–90.
   PubMed Web of Science ®Google Scholar
• Armon C, Graves MC, Moses D, Forte DK, Sepulveda L, Darby SM, Smith RA. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle & Nerve. 2000;23:874–82.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bakker M, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyo- trophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15–21.
   PubMed Web of Science ®Google Scholar
• Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:153–8.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Dib M, Doppler V, Faudet A, Robin V, Salachas F, et al. Tolerance of riluzole in a phase IIIb clinical trial. Therapie. 2002;57:65–71.
   PubMedGoogle Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124(Suppl):96–107.
   Google Scholar
• Paulhan J, Nuissier J, Quintard B, Cousson F, Bourgeois M. La mesure de coping. Traduction et validation franc¸aises de l’e´chelle de Vitaliano. Ann Med Psychol. 1994;152:292–9.
   PubMed Web of Science ®Google Scholar
• Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Medical Care. 1971;18:787–805.
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat. 1979;134:382–9.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini- international interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(Suppl 20):22–33.
   Google Scholar
• Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley, New York., 1989.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V, the ALS/riluzole study group, A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor I on progression of ALS. Neurology. 1997;49:1621–30.
   PubMed Web of Science ®Google Scholar
• Borasio GD, Robberecht W, Leigh PN, et al. A placebo- controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology. 1998;51:583–6.
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study Group, A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46:1244–9.
   PubMedGoogle Scholar
• Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843–8.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyo- trophic lateral sclerosis. Nature Med. 1999;5:347–50.
   PubMed Web of Science ®Google Scholar